Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
21715-46-8
Molecular formula
C17H17ClN2O
Molecular weight
300.8 g/mol
Drug class
Non-benzodiazepine anxiolyticbenzoxazine derivative and GABAergic modulator
Mechanism of action
Enhances GABA-A receptor-mediated inhibitory neurotransmission by two complementary actions: direct interaction with beta-2/beta-3 receptor subunits and indirect modulation through the mitochondrial translocator protein (TSPO), promoting neurosteroid synthesis that positively modulates GABA-A receptors.
Indications / reported uses
Short-term treatment of anxiety symptoms or adjustment disorders with anxiety in countries where etifoxine is authorised; indication, treatment duration and safety restrictions are product- and jurisdiction-specific
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Etifoxine Environmental Risk Assessment (ERA) (the Etifoxine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.